Viking Therapeutics Stock Equity Positions Weight

VKTX Stock

USD 52.94 1.57 2.88%

Viking Therapeutics fundamentals help investors to digest information that contributes to Viking Therapeutics' financial success or failures. It also enables traders to predict the movement of Viking Stock. The fundamental analysis module provides a way to measure Viking Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viking Therapeutics stock.

Other Current Liab Short Long Term Debt Total

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Viking Therapeutics Company Equity Positions Weight Analysis

Viking Therapeutics' Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.

Stock Percentage

% of Equities

in the fund

More About Equity Positions Weight | All Equity Analysis

Viking Equity Positions Weight Driver Correlations

Understanding the fundamental principles of building solid financial models for Viking Therapeutics is extremely important. It helps to project a fair market value of Viking Stock properly, considering its historical fundamentals such as Equity Positions Weight. Since Viking Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Viking Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Viking Therapeutics' interrelated accounts and indicators.

	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Total Assets	Total Current Assets	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Deferred Long Term Liab	Short Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Surpluse	Treasury Stock	Net Invested Capital	Net Working Capital	Capital Stock
Total Stockholder Equity		-0.87	-0.82	0.67	0.31	0.88	1.0	1.0	-0.23	0.88	-0.83	-0.66	0.68	0.95	-0.61	0.9	-0.11	0.98	0.98	-0.61
Net Debt	-0.87		0.96	-0.87	-0.51	-0.79	-0.89	-0.88	0.15	-0.65	0.74	0.59	-0.62	-0.76	0.71	-0.84	0.1	-0.82	-0.82	0.71
Retained Earnings	-0.82	0.96		-0.92	-0.59	-0.78	-0.84	-0.84	0.03	-0.61	0.78	0.67	-0.69	-0.7	0.7	-0.83	0.0	-0.77	-0.77	0.7
Accounts Payable	0.67	-0.87	-0.92		0.72	0.64	0.7	0.7	-0.01	0.45	-0.63	-0.53	0.54	0.54	-0.66	0.69	-0.03	0.6	0.61	-0.66
Total Liab	0.31	-0.51	-0.59	0.72		0.44	0.36	0.35	0.05	0.25	-0.4	-0.34	0.39	0.31	-0.24	0.46	0.02	0.34	0.34	-0.24
Common Stock	0.88	-0.79	-0.78	0.64	0.44		0.88	0.88	-0.16	0.93	-0.91	-0.74	0.83	0.93	-0.24	0.99	0.07	0.92	0.93	-0.24
Total Assets	1.0	-0.89	-0.84	0.7	0.36	0.88		1.0	-0.22	0.88	-0.84	-0.66	0.69	0.94	-0.62	0.9	-0.11	0.97	0.97	-0.62
Total Current Assets	1.0	-0.88	-0.84	0.7	0.35	0.88	1.0		-0.22	0.88	-0.84	-0.66	0.69	0.94	-0.62	0.9	-0.11	0.97	0.97	-0.62
Short Term Debt	-0.23	0.15	0.03	-0.01	0.05	-0.16	-0.22	-0.22		-0.22	-0.16	-0.46	0.4	-0.29	0.01	-0.26	0.83	-0.28	-0.28	0.01
Net Tangible Assets	0.88	-0.65	-0.61	0.45	0.25	0.93	0.88	0.88	-0.22		-0.88	-0.7	0.75	0.94	-0.18	0.91	0.0	0.92	0.93	-0.18
Current Deferred Revenue	-0.83	0.74	0.78	-0.63	-0.4	-0.91	-0.84	-0.84	-0.16	-0.88		0.94	-0.94	-0.81	0.32	-0.88	-0.25	-0.82	-0.83	0.32
Deferred Long Term Liab	-0.66	0.59	0.67	-0.53	-0.34	-0.74	-0.66	-0.66	-0.46	-0.7	0.94		-0.95	-0.62	0.27	-0.68	-0.45	-0.64	-0.64	0.27
Short Long Term Debt	0.68	-0.62	-0.69	0.54	0.39	0.83	0.69	0.69	0.4	0.75	-0.94	-0.95		0.7	-0.19	0.77	0.52	0.7	0.7	-0.19
Short Term Investments	0.95	-0.76	-0.7	0.54	0.31	0.93	0.94	0.94	-0.29	0.94	-0.81	-0.62	0.7		-0.35	0.93	-0.11	0.99	0.99	-0.35
Long Term Debt Total	-0.61	0.71	0.7	-0.66	-0.24	-0.24	-0.62	-0.62	0.01	-0.18	0.32	0.27	-0.19	-0.35		-0.32	0.17	-0.45	-0.45	1.0
Capital Surpluse	0.9	-0.84	-0.83	0.69	0.46	0.99	0.9	0.9	-0.26	0.91	-0.88	-0.68	0.77	0.93	-0.32		-0.05	0.94	0.94	-0.32
Treasury Stock	-0.11	0.1	0.0	-0.03	0.02	0.07	-0.11	-0.11	0.83	0.0	-0.25	-0.45	0.52	-0.11	0.17	-0.05		-0.12	-0.12	0.17
Net Invested Capital	0.98	-0.82	-0.77	0.6	0.34	0.92	0.97	0.97	-0.28	0.92	-0.82	-0.64	0.7	0.99	-0.45	0.94	-0.12		1.0	-0.45
Net Working Capital	0.98	-0.82	-0.77	0.61	0.34	0.93	0.97	0.97	-0.28	0.93	-0.83	-0.64	0.7	0.99	-0.45	0.94	-0.12	1.0		-0.45
Capital Stock	-0.61	0.71	0.7	-0.66	-0.24	-0.24	-0.62	-0.62	0.01	-0.18	0.32	0.27	-0.19	-0.35	1.0	-0.32	0.17	-0.45	-0.45

Click cells to compare fundamentals

Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.

Competition

Predict Viking Therapeutics

According to the company disclosure, Viking Therapeutics has an Equity Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Equity Valuation Now

Equity Valuation

Check real value of public entities based on technical and fundamental data

All Next

Launch Module

Viking Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Viking Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Viking Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Viking Fundamentals

	Return On Equity	-0.15
	Return On Asset	-0.13
	Current Valuation	5.15 B
	Shares Outstanding	111.44 M
	Shares Owned By Insiders	5.96 %
	Shares Owned By Institutions	75.48 %
	Number Of Shares Shorted	16.99 M
	Price To Earning	(3.17) X
	Price To Book	6.66 X
	EBITDA	(100.83 M)
	Net Income	(85.89 M)
	Cash And Equivalents	155.02 M
	Cash Per Share	2.02 X
	Total Debt	1.26 M
	Debt To Equity	0.01 %
	Current Ratio	11.74 X
	Book Value Per Share	8.18 X
	Cash Flow From Operations	(73.38 M)
	Short Ratio	2.85 X
	Earnings Per Share	(0.94) X
	Price To Earnings To Growth	(0.03) X
	Target Price	112.57
	Number Of Employees	30
	Beta	0.99
	Market Capitalization	6.07 B
	Total Asset	368.49 M
	Retained Earnings	(377.94 M)
	Working Capital	348.09 M
	Current Asset	15.2 M
	Current Liabilities	1.98 M
	Net Asset	368.49 M

About Viking Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Viking Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viking Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viking Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC